EYEN = MC $56 M --Cash $18 M-- 1 Drug NDA ready -2x Phase 3 readouts soon

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Dec 16, 2019.

  1. DollarChamp

    DollarChamp Member

    1 Big Drug close to NDA submission expected early next year -- Another 2 Big Drugs in Phase 3 with readouts expected in 2H 2020 -- MASSIVE Insider buying --Low float Stock -- CEO/CMO Ianchulev is the great scientist who lead the development of the mega Blockbuster Lucentis =BRUTALLY UNDERPRICED STOCK WITH MASSIVE UPSIDE POTENTIAL !!! GL


    Eyenovia (EYEN)

    Market Cap $56 M
    Cash $18.4 M
    Price $3.30



    Presentation
    http://ir.eyenoviabio.com/static-files/0ec5c485-6161-4048-95fa-9202d360aae8


    Insider buying
    http://openinsider.com/search?q=eyen


    MicroStat (Indication: Mydriasis) $300 M+ Market Opportunity -Positive Phase 3 results -NDA filing early 2020

    MicroLine (indication:presbyopia) $2 B+ Market Opportunity --Phase 3 results next year

    MicroPine (Indication: Progressive Myopia) $ 5B+ Market Opportunity --Phase 3 results next year



    [​IMG]

    [​IMG]
     
  2. DollarChamp

    DollarChamp Member

    $5.40 ..BIG FDA Decision in 23 days + another 2 potential Blockbuster in Phase 3 nearing readout ..This low float stock could move toward $7-8 ahead of the FDA Decision and with approval the stock could hit $10 ..GL

    Pipeline
    https://assets.wallstreet-online.de...hot-2021-07-27-at-23-04-33-powerpointpres.png


    2 Healthcare Stocks With Big Catalysts in October
    https://finance.yahoo.com/news/2-healthcare-stocks-big-catalysts-130031893.html

    The FDA is expected to make its decision on Eyenovia’s NDA for MydCombi shortly, with a PDUFA date set for October 28. A positive decision will clear the path for commercialization, targeting the extensive potential patient base.

    Ahead of the big day, Ladenburg Thalmann’s Matthew Kaplan backs the drug’s chances and anticipates a successful market entry.

    “We expect MicroStat (Mydcombi) NDA approval and market launch in the U.S. in 4Q21,” the analyst wrote. “The commercial strategy differs from traditional launches as Eyenovia will not hire a sales force; instead, they will maintain ~10 key account managers to initially focus on the largest practices…. With Eyenovia’s plan to price MicroStat on parity to the current eye drops based on their market research, and with an estimated 80 million dilated eye exams and ~4 million surgeries requiring dilation performed each year, we believe it could represent a significant market opportunity for MicroStat.”

    Kaplan gives EYEN shares a Buy rating, with a $19 price target
     

Share This Page